Risk of Serious Infections in Patients Treated With Biologic or Targeted‐synthetic Disease Modifying Antirheumatic Drugs in Qatar

Risk of Serious Infections in Patients Treated With Biologic or Targeted‐synthetic Disease Modifying Antirheumatic Drugs in Qatar

ABSTRACT Background Biologic and targeted‐synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs), are pivotal in the management of autoimmune‐inflammatory disorders, acting by suppressing pathological immune activation. Because of associated immune dysfunction, opportunistic or serious infecti...

Full description

Saved in:
Bibliographic Details
Main Authors: Sreethish Sasi, Hamad Abdel Hadi, Masautso Chaponda, Reem El Ajez, Mohamed Ataelmanan, Sief Khasawneh, Hind Saqallah, Maisa Ali, Nabeel Abdulla, Javed Iqbal, Ali S. Omrani, Muna Al Maslamani, Abdullatif Al‐Khal
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Immunity, Inflammation and Disease
Subjects:
biologic
DMARD
immunocompromised
TNF‐alpha inhibitor
tofacitinib
Online Access:https://doi.org/10.1002/iid3.70195
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items